Literature DB >> 25672820

Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.

Sanjay Verma1,2, Varma S Rudraraju3.   

Abstract

Developing amorphous solid dispersions of water-insoluble molecules using polymeric materials is a well-defined approach to improve the dissolution rate and bioavailability. While the selected polymer plays a vital role in stabilizing the amorphous solid dispersion physically, it is equally important to improve the dissolution profile by inhibiting crystallization from the supersaturated solution generated by dissolution of the amorphous material. Furthermore, understanding the mechanism of dissolution rate enhancement is of vital importance. In this work, wetting kinetics was taken up as an alternative approach for understanding the enhanced dissolution rate for amorphous solid dispersion of a poorly soluble drug. While cilostazol (CIL) was selected as the model drug, povidone (PVP), copovidone, and hypromellose (HPMC) were the polymers of choice. The concentrations against time profiles were evaluated for the supersaturated solutions of CIL in the presence and absence of the selected polymers. The degree of supersaturation increased significantly with increase in polymer content within the solid dispersion. While povidone was found to maintain the highest level of supersaturation for the greatest length of time both in dissolution and solution crystallization experiments, copovidone and hypromellose were found to be the less effective as crystallization inhibitor. The ability of polymers to generate and maintain supersaturated drug solutions was assessed by dissolution studies. The wetting kinetics was compared against the solid dispersion composition to establish a correlation with enhanced dissolution rate.

Entities:  

Keywords:  Cilostazol; Crystallization inhibition; Solid dispersions; Supersaturated solutions; Wetting kinetics

Mesh:

Substances:

Year:  2015        PMID: 25672820      PMCID: PMC4674650          DOI: 10.1208/s12249-014-0281-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  39 in total

Review 1.  Formulation approaches for orally administered poorly soluble drugs.

Authors:  S Pinnamaneni; N G Das; S K Das
Journal:  Pharmazie       Date:  2002-05       Impact factor: 1.267

Review 2.  Amorphous drug delivery systems: molecular aspects, design, and performance.

Authors:  Aditya Mohan Kaushal; Piyush Gupta; Arvind Kumar Bansal
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2004       Impact factor: 4.889

Review 3.  Evaluation of amorphous solid dispersion properties using thermal analysis techniques.

Authors:  Jared A Baird; Lynne S Taylor
Journal:  Adv Drug Deliv Rev       Date:  2011-08-04       Impact factor: 15.470

Review 4.  Characteristics and significance of the amorphous state in pharmaceutical systems.

Authors:  B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1997-01       Impact factor: 3.534

Review 5.  Pharmaceutical applications of solid dispersion systems.

Authors:  W L Chiou; S Riegelman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

6.  Thermally-prepared polymorphic forms of cilostazol.

Authors:  Grayson W Stowell; Robert J Behme; Stacy M Denton; Inigo Pfeiffer; Frederick D Sancilio; Linda B Whittall; Robert R Whittle
Journal:  J Pharm Sci       Date:  2002-12       Impact factor: 3.534

7.  Characterization of ibuproxam binary and ternary dispersions with hydrophilic carriers.

Authors:  M Cirri; P Mura; A M Rabasco; J M Ginés; J R Moyano; M L Gònzalez-Rodrìguez
Journal:  Drug Dev Ind Pharm       Date:  2004-01       Impact factor: 3.225

8.  Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions.

Authors:  Fumié Tanno; Yuichi Nishiyama; Hiroyasu Kokubo; Sakaé Obara
Journal:  Drug Dev Ind Pharm       Date:  2004-01       Impact factor: 3.225

9.  Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug.

Authors:  Hidekazu Toyobuku; Ikumi Tamai; Kazuyuki Ueno; Akira Tsuji
Journal:  J Pharm Sci       Date:  2003-11       Impact factor: 3.534

10.  Physico-chemical properties and stability of cilostazol.

Authors:  T Shimizu; T Osumi; K Niimi; K Nakagawa
Journal:  Arzneimittelforschung       Date:  1985
View more
  8 in total

1.  Thermal Processing of PVP- and HPMC-Based Amorphous Solid Dispersions.

Authors:  Justin S LaFountaine; Leena Kumari Prasad; Chris Brough; Dave A Miller; James W McGinity; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2015-10-13       Impact factor: 3.246

2.  Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways.

Authors:  Khadijah Edueng; Denny Mahlin; Per Larsson; Christel A S Bergström
Journal:  J Control Release       Date:  2017-04-12       Impact factor: 9.776

3.  In-situ freeze-drying - forming amorphous solids directly within capsules: An investigation of dissolution enhancement for a poorly soluble drug.

Authors:  Abdulmalik Alqurshi; K L Andrew Chan; Paul G Royall
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

Review 4.  The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.

Authors:  Khadijah Edueng; Denny Mahlin; Christel A S Bergström
Journal:  Pharm Res       Date:  2017-05-18       Impact factor: 4.200

5.  A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.

Authors:  Emilia Jakubowska; Bartłomiej Milanowski; Janina Lulek
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

6.  Spray Dried Levodopa-Doped Powder Potentially for Intranasal Delivery.

Authors:  Xuan Liu; Shen Yan; Mengyuan Li; Shengyu Zhang; Gang Guo; Quanyi Yin; Zhenbo Tong; Xiao Dong Chen; Winston Duo Wu
Journal:  Pharmaceutics       Date:  2022-06-30       Impact factor: 6.525

7.  The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.

Authors:  Mark Johnson; Roxanne C Jewell; Amanda Peppercorn; Elizabeth Gould; Jianfeng Xu; Yu Lou; Matthew Davies; Sandra Baldwin; Allan R Tenorio; Matthew Burke; Jerry Jeffrey; Brian A Johns
Journal:  Pharmacol Res Perspect       Date:  2018-06-05

Review 8.  Mechanisms of increased bioavailability through amorphous solid dispersions: a review.

Authors:  Andreas Schittny; Jörg Huwyler; Maxim Puchkov
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.